

There is no results summary for study MA41419, EudraCT number 2019-004652-11, because the study was withdrawn (i.e., there were no participants enrolled in this study). Following in-depth consideration of the impact of the mixed results (low efficacy) observed in the etrolizumab Phase III development program, F. Hoffmann-La Roche Ltd. (Sponsor) decided on 01-Sep-2020 to discontinue activities and not proceed with this study.